Full Text View
Tabular View
No Study Results Posted
Related Studies
Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine
This study is ongoing, but not recruiting participants.
Study NCT00168610   Information provided by Bandim Health Project
First Received: September 9, 2005   Last Updated: November 6, 2008   History of Changes

September 9, 2005
November 6, 2008
November 2004
 
  • Mortality
  • Morbidity
Same as current
Complete list of historical versions of study NCT00168610 on ClinicalTrials.gov Archive Site
  • Adverse effects
  • Tuberculin reaction
  • BCG scarring
  • Growth
  • Vitamin A status
  • Cytokine responses
  • Malaria
  • Measles
  • Rotavirus
  • Respiratory syncytial virus (RSV) infection
  • All primary and secondary outcomes will be analysed for interactions between vitamin A and sex and last vaccine received.
  • Adverse effects
  • Tuberculin reaction
  • BCG scarring
  • Growth
  • Vitamin A status
  • Cytokine responses
  • Malaria
  • Measles
  • Rotavirus
  • RSV infection
  • All primary and secondary outcomes will be analysed for interactions between vitamin A and sex and last vaccine received.
 
Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine
Should Infants Receive High-Dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries? Randomized Prospective Studies in Guinea-Bissau

In the present study the investigators wish to address the effects of different doses of vitamin A supplementation in low and normal birth weight infants.

Hypotheses:

  • Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in infant mortality and morbidity during the first year of life in both normal and low birth weight infants.
  • A lower dose of vitamin A may be even more beneficial than a high dose.

Vitamin A deficiency is common in low-income countries. Vitamin A supplementation to children above 6 months of age reduces all-cause mortality by 23% to 30%. Studies on vitamin A supplementation in infants younger than 6 months of age have reported inconsistent effects on mortality. Studies providing supplementation between 1 and 5 months of age have found no effect or even a negative effect. However, the only two studies of supplementation at birth, both conducted in Asia, showed substantial significant reductions in infant all-cause mortality.

The beneficial effect of neonatal vitamin A supplementation may be a result of correcting the congenital vitamin A deficiency resulting from maternal vitamin A deficiency. On the other hand, it has been speculated that the beneficial effect of vitamin A supplementation given at birth may in part be explained by a synergistic effect of vitamin A supplementation and BCG vaccination given at the time of birth.

The protective effect on mortality of vitamin A supplementation given at birth needs to be confirmed in an African population. Furthermore, none of the two previous studies have reported data on the vaccination status of the included infants.

In the proposed studies, the effect on mortality and morbidity of giving vitamin A supplementation simultaneously with BCG vaccination at birth to both normal and low birth weight infants will be investigated in an African population. Furthermore, the effects of vitamin A supplementation will be evaluated with respect to effect on growth, the response to BCG vaccination, infant vitamin A status and infant cytokine profile, malaria, measles, rotavirus infection and RSV infection. The mechanisms behind the effects of vitamin A will be evaluated. The potential interactions between vitamin A, sex and vaccines will be taken into account in all analyses.

This will be done in two studies of newborn children. Study A includes 6,000 normal birth weight infants (> 2500 g) randomized to 50,000 or 25,000 IU vitamin A or placebo given simultaneously with BCG vaccine. Study B includes 1,600 low birth weight infants (< 2500 g) randomized to vitamin A or placebo and early BCG or late BCG in a two-by-two factorial design. The studies take place in Guinea-Bissau, West Africa. The study area consists of five districts in the capital of Guinea-Bissau. The Bandim Health Project has been working in the study area for almost 25 years, and a demographic surveillance system has been established and has functioned for many years.

Phase IV
Interventional
Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment
  • Infant Mortality
  • Morbidity
Drug: Vitamin A
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
7600
 
 

Inclusion Criteria:

  • Normal birth weight: belonging to the study area
  • Low birth weight: being born at the national hospital

Exclusion Criteria:

  • Overt illness
  • Signs of vitamin A deficiency
  • Previous BCG vaccination
Both
up to 5 Months
No
Contact information is only displayed when the study is recruiting subjects
Guinea-Bissau
 
NCT00168610
 
6-FY04-51-VITA2, 6-FY04-51
Bandim Health Project
  • March of Dimes
  • Leiden University Medical Center
  • Medical Research Council Laboratories, Gambia
Principal Investigator: Peter Aaby Bandim Health Project
Bandim Health Project
November 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP